Among the compounds generating serious interest in metabolic research circles, 5-Amino-1MQ occupies a unique position. It’s not a peptide, not a SARM, and not a traditional stimulant — it’s a small-molecule NNMT inhibitor, and what it does to the body’s NAD+ economy has scientists rethinking how we approach fat metabolism, energy regulation, and cellular aging. This article compiles what the research actually shows.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective, cell-permeable inhibitor of Nicotinamide N-methyltransferase (NNMT) — an enzyme that plays a central role in regulating NAD+ availability and one-carbon metabolism. When NNMT activity is high, it consumes SAM (S-adenosylmethionine) and nicotinamide, effectively draining the substrates needed to produce NAD+. By blocking NNMT, 5-Amino-1MQ shifts this balance: NAD+ precursors become more available, sirtuin activity increases, and downstream metabolic signaling changes substantially.
The compound was first developed in academic labs exploring obesity and metabolic syndrome, where NNMT overexpression in adipose tissue had been identified as a driver of fat accumulation and insulin resistance. 5-Amino-1MQ offered a way to probe what happens when you remove that brake — and the early results were striking enough to attract continued investment in the research.
Research Overview
The most cited foundational work comes from Neelakantan et al. (2019), published in Nature Communications, which demonstrated that NNMT inhibition with a related compound in diet-induced obese mice produced significant reductions in body weight and fat mass without changes to food intake — a result that pointed directly to metabolic rate enhancement rather than appetite suppression. The mechanism involved elevated NAD+ levels in adipose tissue, increased SIRT1 activity, and upregulation of thermogenic gene expression. (PubMed: 30980044)
Subsequent work has refined the picture. Studies examining NNMT’s role in skeletal muscle, liver, and adipose tissue have shown that the enzyme is highly context-dependent — its expression correlates with obesity, type 2 diabetes, and aging-related metabolic decline across multiple tissue types. Inhibiting it pharmacologically appears to restore the NAD+/NADH ratio and improve mitochondrial function in ways that parallel the effects of NAD+ precursor supplementation but through a distinct mechanism. (Google Scholar: NNMT inhibitor research)
More recent preclinical data has explored 5-Amino-1MQ specifically in the context of diet-induced obesity models, showing dose-dependent reductions in adiposity, improvements in glucose tolerance, and favorable lipid profiles — all without apparent hepatotoxicity at studied doses. Research into its pharmacokinetics confirms good cell permeability and reasonable oral bioavailability in rodent models, making it a tractable candidate for further study.
Community Discussion
The research community and self-experimenters on platforms like Reddit have been discussing 5-Amino-1MQ with notable interest, particularly among those already familiar with NAD+ biology and SIRT1 activation. Threads on r/Peptides and r/longevity discuss its positioning relative to NMN and NR supplementation, with many noting that NNMT inhibition targets the consumption side of NAD+ metabolism rather than just boosting supply — a fundamentally different angle. Discussions around dosing, timing, and combination protocols are ongoing.
Potential Benefits Studied
- Fat mass reduction without caloric restriction: Animal studies consistently show reductions in adiposity independent of food intake changes, suggesting direct metabolic rate effects.
- NAD+ elevation in target tissues: NNMT inhibition increases the availability of nicotinamide for NAD+ synthesis, raising intracellular NAD+ levels particularly in adipose and muscle tissue.
- Sirtuin pathway activation: Higher NAD+ drives SIRT1 and SIRT3 activity, which regulate mitochondrial biogenesis, fatty acid oxidation, and inflammatory signaling.
- Improved insulin sensitivity: Preclinical models of diet-induced obesity show improved glucose tolerance and insulin response following NNMT inhibition.
- Thermogenic gene upregulation: Research shows increased expression of UCP1 and other thermogenic markers in adipose tissue, consistent with enhanced brown-fat-like activity.
- Potential anti-aging applications: Given NNMT’s role in the aging metabolic phenotype, inhibition is being studied in the context of healthspan extension and age-related metabolic decline.
- Favorable safety profile in models studied: No significant hepatotoxicity, cardiotoxicity, or reproductive effects observed at research doses in animal studies to date.
Dosage & Administration
Human dosing for 5-Amino-1MQ has not been established through clinical trials, and all information here is derived from preclinical research and emerging community protocols for research purposes. Animal studies have used doses ranging from approximately 50–200 mg/kg in rodent models; human equivalent dose calculations suggest much lower amounts would apply due to allometric scaling differences, though direct extrapolation remains speculative without clinical data.
The compound is typically available in oral capsule or tablet form. Research protocols explored in community settings often describe administration once or twice daily, with some researchers noting anecdotal observations of increased thermogenesis and energy expenditure within the first week of use. Cycling protocols are commonly discussed, with periods of use followed by breaks to prevent potential receptor adaptation.
Where to Find It
5-Amino-1MQ 50MG is available for research purposes at combatresearch.is. Combat Research provides this compound as part of their catalog of research-grade materials for qualified researchers and institutions.
Conclusion
5-Amino-1MQ represents one of the more mechanistically compelling compounds in the metabolic research space. Rather than flooding the system with NAD+ precursors or mimicking downstream effects, it targets NNMT — the enzyme that actively consumes the raw materials needed for NAD+ production in adipose and metabolic tissue. The preclinical data showing fat mass reduction without caloric restriction, improved insulin sensitivity, and sirtuin activation paint a picture that warrants continued investigation. For researchers focused on metabolic health, obesity, and longevity biology, 5-Amino-1MQ is a compound worth understanding in depth.
Disclaimer: This article is for educational and informational purposes only. 5-Amino-1MQ is a research compound and has not been approved by the FDA for human use. This content does not constitute medical advice. All research should be conducted in accordance with applicable regulations and ethical guidelines. Do not use this compound for any purpose other than legitimate scientific research.
